Ascentage Pharma Group Inc.

AAPG · China

Share price · AAPG

$13.01-5.19 (-28.50%) 3M

close as of 2026-11-18 · 24h delayed · vol 2K (0.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AAPG's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026+11.8%
  2. 6 Oct 2026+10.2%
  3. 27 Aug 2026+10.8%
  4. 7 Aug 2026+11.1%
  5. 17 Jul 2026-8.1%
  6. 10 Jul 2026+5.7%
  7. 23 Apr 2026-11.1%
  8. 1 Apr 2026+10.1%
  9. 27 Mar 2026+8.2%
  10. 23 Mar 2026+16.8%

Share of unusual movement by asset

For each asset, the share of AAPG's own-move activity since 27 Jan 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Lisaftoclax
events and moves
136%
Olverembatinib
events and moves
134%
Alrizomadlin
events and moves
2shown from 8 days
APG-2449
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—29%
Sessions with no dated event—60%

Assets

(5 total)
5Total Assets
0Approved
3Phase 3 / Filed
2Phase 1–2 / Early
7Diseases
Quick filter:
Showing 5 of 5 assets
Target & Modality
Phase 3
FAK / ALK / ROS1Small molecule
Non-Small Cell Lung CancerOvarian Cancer
Phase 3
BCL-2Small molecule
Acute Myeloid LeukemiaMultiple MyelomaSystemic Lupus ErythematosusChronic Lymphocytic Leukemia
Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 3
BCR-ABL (also AKT, c-Kit, ERK)Small molecule
Acute Myeloid LeukemiaChronic Myeloid Leukemia
Chronic Myeloid Leukemia with T315I Mutation
Phase 1/2
MDM2Small molecule
Acute Myeloid Leukemia
Phase 1
Bcl-2 / Bcl-xLSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
LisaftoclaxPhase 2Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Est. primary completion 2026-12 · NCT05147467 · CT.gov ↗
What to watch
LisaftoclaxPhase 3CLL/SLL
Est. primary completion 2026-12-31 · NCT06104566 · CT.gov ↗
What to watch
2027 (5)
March 2027 (1)
OlverembatinibPhase 3GIST
Est. primary completion 2027-03-31 · NCT06640361 · CT.gov ↗
What to watch
June 2027 (2)
Lisaftoclax + AlrizomadlinPhase 1/2Neuroblastoma, Solid Tumor
Est. primary completion 2027-06-01 · NCT05701306 · CT.gov ↗
What to watch
OlverembatinibPhase 3Chronic Myeloid Leukemia, CML, CML, Chronic Phase
Est. primary completion 2027-06-30 · NCT06423911 · CT.gov ↗
What to watch
August 2027 (1)
LisaftoclaxPhase 3CLL/SLL
Est. primary completion 2027-08 · NCT06319456 · CT.gov ↗
What to watch
December 2027 (1)
OlverembatinibPhase 3Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Est. primary completion 2027-12-31 · NCT06051409 · CT.gov ↗
What to watch
2028 (2)
May 2028 (1)
LisaftoclaxPhase 3Acute Myeloid Leukemia
Est. primary completion 2028-05-25 · NCT06389292 · CT.gov ↗
What to watch
September 2028 (1)
Lisaftoclax + OlverembatinibPhase 1/2Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Est. primary completion 2028-09 · NCT04501120 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
LisaftoclaxPhase 3Higher-risk Myelodysplastic Syndrome
Est. primary completion 2029-06 · NCT06641414 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Annual history (4 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$136M$132M$122M$14M-$16M operating cash flowreport ↗
View 3 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$31M$100M$146M$33M-$103M operating cash flowreport ↗
2022-FY$31M$111M$193M$33M-$97M operating cash flowreport ↗
2021-FY——$268M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-05-21Yang Dajun · director, Chairman and CEOOption exercise95,575——Form 4
2026-05-21Zhai Yifan · Chief Medical OfficerOption exercise92,746——Form 4
2026-05-21Yang Dajun · director, Chairman and CEOOption exercise92,746——Form 4
2026-05-21Zhai Yifan · Chief Medical OfficerOption exercise95,575——Form 4
2026-05-21Yang Dajun · director, Chairman and CEOOption exercise (derivative)95,575——Form 4
2026-05-21Zhai Yifan · Chief Medical OfficerOption exercise (derivative)92,746——Form 4
2026-05-21Zhai Yifan · Chief Medical OfficerOption exercise (derivative)95,575——Form 4
2026-05-21Yang Dajun · director, Chairman and CEOOption exercise (derivative)92,746——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 7 reporting institutions held 0.0M shares ($722K).

#InstitutionSharesValue
1Point72 Asset Management, L.P.16,056$383K
2XY Capital Ltd13,014$311K
3Tower Research Capital LLC (TRC)518$12K
4MORGAN STANLEY498$12K
5UBS Group AG124$3K
6EverSource Wealth Advisors, LLC24$573
7ROYAL BANK OF CANADA6$0